AbbVie Inc.
DOSING REGIMENS FOR USE IN TREATING MYELOFIBROSIS AND MPN-RELATED DISORDERS WITH NAVITOCLAX
Last updated:
Abstract:
The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.
Status:
Application
Type:
Utility
Filling date:
4 Nov 2020
Issue date:
6 May 2021